125 related articles for article (PubMed ID: 30026110)
1. Repurposing Nilotinib for Cytomegalovirus Infection Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Arm, Phase II Trial.
Lin CT; Hsueh PR; Wu SJ; Yao M; Ko BS; Li CC; Hsu CA; Tang JL; Tien HF
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2310-2315. PubMed ID: 30026110
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus.
Liu YC; Lu PL; Hsiao HH; Chang CS; Liu TC; Yang WC; Lin SF
Ann Hematol; 2012 Apr; 91(4):587-95. PubMed ID: 21997849
[TBL] [Abstract][Full Text] [Related]
3. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study.
Junghanss C; Boeckh M; Carter RA; Sandmaier BM; Maris MB; Maloney DG; Chauncey T; McSweeney PA; Little MT; Corey L; Storb R
Blood; 2002 Mar; 99(6):1978-85. PubMed ID: 11877269
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
5. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.
Boeckh M; Bowden RA; Storer B; Chao NJ; Spielberger R; Tierney DK; Gallez-Hawkins G; Cunningham T; Blume KG; Levitt D; Zaia JA
Biol Blood Marrow Transplant; 2001; 7(6):343-51. PubMed ID: 11464977
[TBL] [Abstract][Full Text] [Related]
6. Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase.
Xu L; Zhu H; Hu J; Wu D; Jiang H; Jiang Q; Huang X
Front Med; 2015 Sep; 9(3):304-11. PubMed ID: 26100855
[TBL] [Abstract][Full Text] [Related]
7. [Application of real time polymerase chain reaction to the diagnosis and treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation].
Chen H; Liu KY; Xu LP; Liu DH; Chen YH; Zhao XS; Yu L; Han W; Zhang XH; Wang Y; Chen Y; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2009 Feb; 30(2):77-81. PubMed ID: 19563015
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic letermovir decreases cytomegalovirus reactivation after stem cell transplantation: a single-center real-world evidence study.
Serio B; Giudice V; Guariglia R; Fontana R; Pezzullo L; Martorelli MC; Ferrara I; Mettivier L; D'Addona M; Vaccaro E; Langella M; Selleri C
Infez Med; 2021 Mar; 29(1):102-113. PubMed ID: 33664179
[TBL] [Abstract][Full Text] [Related]
9. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
10. Possible Impact of Cytomegalovirus-Specific CD8
Ogonek J; Varanasi P; Luther S; Schweier P; Kühnau W; Göhring G; Dammann E; Stadler M; Ganser A; Borchers S; Koehl U; Weissinger EM; Hambach L
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1046-1053. PubMed ID: 28344058
[TBL] [Abstract][Full Text] [Related]
11. Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Leukemia.
Inagaki J; Noguchi M; Kurauchi K; Tanioka S; Fukano R; Okamura J
Biol Blood Marrow Transplant; 2016 Feb; 22(2):300-306. PubMed ID: 26371373
[TBL] [Abstract][Full Text] [Related]
12. Incidence of CMV Replication and the Role of Letermovir Primary/Secondary Prophylaxis in the Early Phase After Allogeneic Hematopoietic Stem Cell Transplantation - A Single Centre Study.
Studer U; Khanna N; Leuzinger K; Hirsch HH; Heim D; Lengerke C; Tsakiris DA; Halter J; Gerull S; Passweg J; Medinger M; Gwerder M
Anticancer Res; 2020 Oct; 40(10):5909-5917. PubMed ID: 32988922
[TBL] [Abstract][Full Text] [Related]
13. Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia.
Lin CH; Su YJ; Hsu CY; Wang PN; Teng CJ
Transpl Infect Dis; 2019 Aug; 21(4):e13096. PubMed ID: 31004545
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus Reactivation Is Associated with Increased Risk of Late-Onset Invasive Fungal Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Study in the Current Era of Viral Load Monitoring.
Yong MK; Ananda-Rajah M; Cameron PU; Morrissey CO; Spencer A; Ritchie D; Cheng AC; Lewin SR; Slavin M
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1961-1967. PubMed ID: 28797778
[TBL] [Abstract][Full Text] [Related]
15. Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shimoni A; Volchek Y; Koren-Michowitz M; Varda-Bloom N; Somech R; Shem-Tov N; Yerushalmi R; Nagler A
Cancer; 2015 Mar; 121(6):863-71. PubMed ID: 25387866
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of inflammatory biomarkers in plasma predict the occurrence and features of cytomegalovirus DNAemia episodes in allogeneic hematopoietic stem cell transplant recipients.
Talaya A; Giménez E; Vinuesa V; Pérez A; Amat P; Piñana JL; Albert E; Hernández-Boluda JC; Solano C; Navarro D
Med Microbiol Immunol; 2019 Aug; 208(3-4):405-414. PubMed ID: 30911925
[TBL] [Abstract][Full Text] [Related]
17. Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease and non-relapse mortality.
Liu J; Kong J; Chang YJ; Chen H; Chen YH; Han W; Wang Y; Yan CH; Wang JZ; Wang FR; Chen Y; Zhang XH; Xu LP; Liu KY; Huang XJ
Clin Microbiol Infect; 2015 Dec; 21(12):1121.e9-15. PubMed ID: 26093077
[TBL] [Abstract][Full Text] [Related]
18. Low-dose valgancyclovir as cytomegalovirus reactivation prophylaxis in allogeneic haematopoietic stem cell transplantation.
Serio B; Rosamilio R; Giudice V; Pepe S; Zeppa P; Esposiito S; Pezzullo L; Rocco M; Montuori N; Selleri C
Infez Med; 2012; 20 Suppl 2():26-34. PubMed ID: 23042003
[TBL] [Abstract][Full Text] [Related]
19. An investigation of the utility of plasma Cytomegalovirus (CMV) microRNA detection to predict CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients.
Talaya A; Giménez E; Pascual MJ; Gago B; Piñana JL; Hernández-Boluda JC; Vázquez L; García M; Serrano D; Hernández M; Albert E; Solano C; Navarro D
Med Microbiol Immunol; 2020 Feb; 209(1):15-21. PubMed ID: 31478067
[TBL] [Abstract][Full Text] [Related]
20. Rapid Acquisition of Cytomegalovirus-Specific T Cells with a Differentiated Phenotype, in Nonviremic Hematopoietic Stem Transplant Recipients Vaccinated with CMVPepVax.
La Rosa C; Longmate J; Lingaraju CR; Zhou Q; Kaltcheva T; Hardwick N; Aldoss I; Nakamura R; Diamond DJ
Biol Blood Marrow Transplant; 2019 Apr; 25(4):771-784. PubMed ID: 30562587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
